Visudyne labelling to be changed

Article

QLT has announced that the Committee for Medicinal Products for Human Use (CHMP) will recommend to the European Commission that the occult indication for Visudyne be removed from the product's European label.

QLT has announced that the Committee for Medicinal Products for Human Use (CHMP) will recommend to the European Commission that the occult indication for Visudyne be removed from the product's European label.

The CHMP opinion was based on its review of data from the Visudyne in Occult trial, which did not achieve the significance level required of its primary endpoints. The European Commission is expected to endorse the recommendation in a final decision to be announced in the coming months.

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
Abdelrahman Elhusseiny, MD, MSc, discusses his AAO presentation on risk of posterior capsular rupture in fellow-eyes cataract surgery
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
AAO 2024: Approaching pregnant women across the ophthalmic subspecialties

AAO 2024: Approaching pregnant women across the ophthalmic subspecialties

Sydney M Crago
October 22nd 2024
Article

Dr. Arepalli discussed a course focused on ocular conditions related to pregnancy and postpartum care, presented at the American Academy of Ophthalmology (AAO) meeting.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The AAO logo and Giovanni Montesano, MD, Moorfields Eye Hospital and City, University of London

Six-year findings from laser in glaucoma and ocular hypertension (LiGHT)

By Lynda Charters; reviewed by Giovanni Montesano, MD
October 20th 2024
Article

In visual field progression results, SLT was superior to ocular drops as first-line treatment for patients with glaucoma

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A person holding a cell phone next to the AAO logo. Stock image credit: ©ARAMYAN – stock.adobe.com. Logo courtesy American Academy of Ophthalmology.

Focus, academic perfomance and mental health outcomes in classroom cell phone use

Lynda Charters
October 18th 2024
Article

The research found that, in the classroom, when learning-focused cell phone use increased, social use decreased

AAO launches VR education program in collaboration with FundamentalVR to improve worldwide ophthalmic care

AAO launches VR education program in collaboration with FundamentalVR to improve worldwide ophthalmic care

Lynda Charters
October 18th 2024
Article

This initiative is supported by a $5 million grant from the Knights Templar Eye Foundation.

© 2024 MJH Life Sciences

All rights reserved.